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Abstract
Residues within the highly conserved C3 region of human and simian immunodeficiency virus (HIV, SIV) envelope proteins (Envs) bind
directly to the cellular CD4 receptor. However, substitutions of D385, which is critical for CD4 engagement along with other changes such
as G382R, G383R, frequently arise in SIV mac-infected macaques. We investigated the influence of substitutions in the SIVmac and HIV-1
C3 regions on viral entry, dependence on CD4, and replication. Mutations flanking the C3 region such as G382R or V388A enhanced and
changes within the C3 region (i.e., G383R or D385N) impaired SIVmac infectivity. Several naturally occurring sequence variations in the
SIVmac Env C3 region facilitated CD4-independent membrane fusion but abrogated viral replication, suggesting that efficient infection
requires additional changes elsewhere in Env. Substitutions of S365R and D368G in the HIV-1 Env, which correspond to G382 and D385
in SIVmac Env, consistently impaired viral infectivity. In contrast, mutation of D368N resulted in a virus that could not spread in cells
expressing low levels of CD4, but which replicated efficiently when high levels of CD4 were expressed. Thus, changes in the C3 region
of HIV-1 or SIVmac Env can have differential effects on viral infectivity and CD4-dependency. We conclude that substitutions flanking the
C3 region in SIVmac Env such as G382R or V388A represent one step toward adaptation to growth in target cells expressing low CD4
levels, whereas changes within the C3 region that disrupt CD4 binding might indicate the emergence of CD4-independent variants at later
stages of infection, which could potentially broaden viral tropism.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Human immunodeficiency virus type 1 (HIV-1), the
main causative agent of AIDS, and the related simian im-
munodeficiency viruses (SIV) infect target cells by binding
of the external envelope glycoprotein (gp120) to the cellular
CD4 receptor and subsequent interactions with chemokine
receptors (Berger et al., 1999; Doms and Peiper, 1997).
Mutational analysis has shown that binding of gp120 to
CD4 involves a specific interaction between the second
complementarity-determining region (CDR2) of CD4 and
several conserved discontinuous epitopes in the HIV-1 en-
velope glycoprotein (Cordonnier et al., 1989; Kowalski et
al., 1987; Moebius et al., 1992). Structural analysis of the
gp120–CD4 complex demonstrated that residues D368 and
E370 in the C3 region (G366GDPE370) of the HIV-1 Env
make multiple contacts with amino acid residues F43 and
R59 located in CDR2 of the CD4 receptor molecule
(Kwong et al., 1998). The C3 region in gp120 is highly
conserved between HIV-1 and SIV. Consequently, substi-
tutions in the C3 region similar to D368N in the HIV-1
gp120 and the analogous D385N change in the SIVmac Env
impair CD4 binding and viral infectivity (Morrison et al.,
1995; Olshevsky et al., 1990; Ryzhova et al., 2002).
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In light of the critical role of these residues in CD4
binding, it is striking that substitutions of D385 in conjunc-
tion with other changes in the C3 region are frequently
observed in tissues of rhesus macaques with simian AIDS
and might be associated with a tropism for specific organs
and altered pathogenicity (Anderson et al., 1993; Campbell
and Hirsch, 1994; Kodama et al., 1993; Rudensey et al.,
1995; Zhu et al., 1995). Notably, Envs from neurotropic,
highly pathogenic SIVmac variants harboring the G383R
and D385N changes in the C3 region, together with other
substitutions in the C1 domain, the V1/V2 loop, and gp41,
showed diminished CD4 binding and were able to use
CCR5 in the absence of CD4 for cell–cell fusion (Ryzhova
et al., 2002). Therefore, these changes might reflect the
evolution of CD4-independent viral variants with a broad-
ened cellular tropism. However, in this previous study it
was not addressed whether the G383R and D385N substi-
tutions alone are sufficient to mediate CD4-independent
fusion and SIV infection. In contrast to the situation ob-
served with SIV, changes in the HIV-1 C3 region are usu-
ally not selected for in HIV-1-infected individuals, suggest-
ing that these alterations might compromise viral spread
during all stages of infection.
In this article, we show that changes in the C3 region
might facilitate CD4-independent fusion and that the
G382R substitution in the SIVmac Env can partly compen-
sate for the inactivating D385N mutation. In comparison,
the corresponding S365R change in the HIV-1 NL4-3 Env
did not restore viral infectivity. Substitution of D368N
alone in the HIV-1 gp120 had differential effects on viral
entry and replication. The D368N variant was inactive in
cells expressing low levels of CD4 but replicated more
efficiently than the parental NL4-3 clone in cells expressing
high levels of CD4. These results suggest that specific
changes in the HIV-1 C3 region might be advantageous for
viral replication in primary cells or tissues that contain high
surface levels of the CD4 receptor molecule. The alterations
in or near the SIVmac C3 region selected in infected ma-
caques seem to reflect a stepwise adaptation to CD4-inde-
pendent entry.
Results
Substitution of G382R partially compensates for the
D385N mutation in the SIVmac gp120 C3 region
Alterations in or near the C3 region became predominant
in brain, colon, and other tissues derived from macaques
displaying severe encephalomyelitis or enterocolitis after
infection with the pathogenic SIVmac239 clone (Anderson
et al., 1993; Campbell and Hirsch, 1994; Kodama et al.,
1993; Rudensey et al., 1995; Zhu et al., 1995), which re-
quires CD4 and CCR5 for efficient infection (Chen et al.,
1997; Hill et al., 1997; Kirchhoff et al., 1997; Marcon et al.,
1997). Since this region is important for CD4 binding, we
generated a collection of 14 full-length, replication-compe-
tent SIVmac239 variants containing changes in the critical
gp120 D385 residue and alterations in or near the C3 region
that have been previously identified in vivo in infected
macaques (Fig. 1A). Our goal was to assess the impact of
these changes on viral infectivity, replication, and CD4-
dependency. We used CCR5 and CD4 of human (hu) and
rhesus macaque (rh) origin because, while both support
SIVmac239 infection, subtle differences between these re-
ceptors might affect the efficiency with which some SIV
strains infect cells, particularly in the absence of CD4
(Edinger et al., 1997). Sequence analysis confirmed that all
variants differed from the parental SIVmac239 clone exclu-
sively by the specific changes at amino acid residues 382,
383, 385, and 388 in the gp120. Western blot analysis
Fig. 1. (A) Amino acid substitutions in the SIVmac C3 region. Mutations detected in vivo in infected macaques are marked with an asterisk. Dashes indicate
identity to the C3 sequence of SIVmac239 (Regier et al., 1990). The numbers above the alignment specify the position in the SIVmac239 Env. (B, C) Entry
of SIVmac239 C3 variants into transiently transfected 293T cells coexpressing (B) rhesus or (C) human CD4 and human CCR5. 293T cells were transfected
with plasmids expressing human CD4 and the entry cofactors indicated. At 1 day posttransfection the cells were detached from the plates, seeded in 48-well
dishes, and infected in triplicate with replication-competent SIV carrying the luciferase gene in place of the nef gene. Virus stocks containing normalized
amounts of p27 antigen (300 ng) were used for infection. Luciferase activities in the cellular extracts were measured at 3 days postinfection. Results were
confirmed by two independent experiments.
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revealed that all mutant Env proteins were efficiently ex-
pressed and processed (data not shown).
The effect of alterations in the CD4-binding site on viral
infectivity was first assessed by infection of sMAGI indi-
cator cells (Chackerian et al., 1995) expressing human CD4
together with rhesus macaque coreceptors. We found that
mutation of G382R and V388A flanking the critical D385
residue enhanced viral infectivity, while SIVmac239 con-
taining either the G383R or the G382R mutation entered the
cells with an efficiency comparable to 239wt (data not
shown). Entry of all remaining mutants, including D385N,
was at least five-fold reduced. Next, we infected 293T cells
expressing rh or hu CD4 with the SIVmac C3 variants
containing the luciferase reporter gene in place of nef. Only
the G382R and V388A variants infected 293T cells express-
ing rhCD4 and huCCR5 with an efficiency comparable to
wild-type SIVmac239 (239wt) (Fig. 1B). Substitutions of
G383R, G382R/G383R, and D385E reduced SIVmac239
infectivity about 6- to 14-fold. All other C3 variants were
grossly defective in viral entry into cells expressing rhCD4.
Comparable results were obtained with cells coexpressing
rhCD4 and huGPR15 (data not shown). Notably, SIVmac
containing mutations of G383R or D385E entered effi-
ciently into cells expressing huCD4 (Fig. 1C), whereas
infection via rhCD4 was clearly diminished (Fig. 1B). This
finding is unexpected because it has been suggested that the
G383R change impairs SIVmac gp120 binding to huCD4
(Ryzhova et al., 2002).
The disruptive effect of the D385N substitution was
partly compensated for by the G382R change. The D385N
mutant virus showed 0.5% infectivity, relative to 239wt
infection, irrespective of whether CD4 and coreceptor were
of human or rhesus origin (Figs. 1B and C). In comparison,
the 382RxxN variant infected CCR5 expressing cells via
rhCD4 with 2.6  0.8% efficiency and target cells express-
ing huCD4 with 55.6  2.9% of 239wt efficiency (Fig. 1).
Indeed, results from five independent experiments per-
formed with coreceptors of both rhesus and human origin in
various combinations revealed that the additional mutation
of G382R enhanced the infectivity of the D385N variant for
target cells expressing rhCD4 about 10- to 50-fold and for
huCD4 between 500- and 3000-fold. In contrast, the adja-
cent mutation of G383R had no restorative effects on SIV-
mac D385N infectivity.
We next used an ELISA assay to investigate whether the
infectivity of the G382R, G383R, D385N, and the RxxN C3
Env variants correlated with their ability to bind to rhCD4.
The G382R change slightly reduced SIVmac gp120 binding
to rhCD4 (Fig. 2). In contrast, the G383R change strongly
impaired and mutation of D385N fully disrupted rhCD4
binding, thus correlating with their effects on viral infectiv-
ity. The introduction of the G382R substitution into the
D385N Env background slightly increased CD4 binding
(Fig. 2). Similar results were obtained when huCD4 was
utilized in the binding assay (data not shown).
Substitution of D385 induces CD4-independent cell–cell
fusion but does not allow efficient infection of CD4-
negative target cells
Ryzhova et al., (2002) have recently reported that SIV-
mac Envs containing changes of G383R or D385N show a
CD4-independent phenotype. However, compared with the
parental SIVmac239 clone, these envelopes contained ad-
ditional changes in the C1 domain and in the V1/V2 loop as
well as in gp41, which could contribute to their ability to
utilize CCR5 in the absence of CD4. To address this, we
investigated whether alterations in the SIVmac C3 Env
region alone might allow CD4-independent fusion. As
shown in Fig. 3, efficient fusion mediated by the 239wt,
G383R, G382R, and V388A Env proteins required the pres-
ence of CD4. In contrast, analysis of the D385G, 382RR,
382RRxN, 382RxxN, 383RxN, D385N, and D385E mutant
Envs revealed comparable levels of CCR5-mediated fusion
in the presence or absence of CD4 (Fig. 3). The combination
of the G383R and D385N mutations did not augment CD4-
independence compared to the single D385N mutation. No-
tably, mutation of G382R and V388A generally enhanced
cell–cell fusion, whereas all remaining C3 mutant Envs
were less active than 239wt Env in the presence of CD4 and
CCR5. The results show that alterations of D385 impair
CD4-dependent and enhance CD4-independent cell–cell fu-
sion, whereas substitutions of G382R and V388A flanking
the C3 region generally enhance fusogenic activity.
The cell–cell fusion assay usually results in overexpres-
sion of both Env and coreceptor likely maximizing the assay
sensitivity (Puffer et al., 2002; Rucker et al., 1997). We
infected 293T cells transiently expressing rhesus or human
CCR5 with luciferase reporter viruses to determine whether
CD4-independent fusion was also observed under less arti-
ficial conditions. Infection of cells expressing both CD4 and
CCR5 with 239wt virus typically resulted in luciferase ac-
tivities 100,000 counts per second (cps) in the cellular
Fig. 2. Binding of SIVmac C3 variant Env proteins to rhCD4. Soluble
gp120 proteins were generated and tested for rhCD4IgG binding in an
ELISA as described under Materials and methods. OD630, optical density at
630 nm. Similar results were obtained with huCD4.
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extracts. In contrast, the detectable levels of luciferase ac-
tivity were generally 300 cps in the absence of CD4 even
when very high viral multiplicities were used for infection
with SIVmac 239wt or the C3 variants (data not shown).
Taken together, our results demonstrate that changes in the
SIVmac Env C3 region can facilitate CD4-independent
cell–cell fusion but do not allow significant levels of viral
infection or replication in the absence of CD4.
While mutations in the C3 region did not confer a de-
tectable CD4-independent phenotype to SIVmac239, it is
possible that they might lead to more efficient utilization of
CD4 when this receptor is expressed at low levels. Indeed,
more efficient use of limiting levels of CD4 has been linked
to macrophage tropism in the SIV system (Banner et al.,
2000; Mori et al., 2000). Therefore, we examined the ability
of the mutant C3 SIVmac Envs to mediate fusion at limiting
levels of rhCD4. As shown in Fig. 4A, comparable levels of
cell–cell fusion were observed in cells transfected with 1.0
or 0.1 g rhCCR5 expression plasmid, suggesting that co-
receptor expression levels were not limiting. In contrast,
fusion mediated by the 239wt, G382R, and V388A Env
proteins declined as the level of CD4 decreased. In com-
parison, the G383R, 383RxN, and D385N Envs were less
sensitive toward the decrease in CD4 levels (Fig. 4A). In
agreement with the findings mentioned above, the 383RxN
and D385N Envs were less and the G382R and V388A Env
proteins were more active in mediating cell–cell fusion.
Next, we tested the sensitivity of G382R Env to neutraliza-
Fig. 3. CD4-independent CCR5 use by SIVmac C3 variant Envs. The fusion assay was performed by using quail QT6 target cells transiently expressing rhesus
CD4 and CCR5 as described previously (Puffer et al., 2002; Rucker et al., 1997). Data from three experiments were averaged and the standard error of the
mean was calculated. All values were normalized to levels of fusion detected for the 239wt Env in the presence of both CD4 and CCR5.
Fig. 4. Analysis of fusion at limiting levels of rhCD4 and neutralization sensitivity. (A) Target cells were transfected with the designated amounts of plasmids
expressing rhCD4 and rhCCR5 and fusions assays were performed in duplicate as described in the legend to Fig. 4. (B) The SIVmac239 G382R variant is
less susceptible to neutralization by MAb SK3 than 239wt. The ability of MAb SK3 to inhibit infection of P4-CCR5 cells by SIVmac 239wt or G382R was
tested at the indicated dilutions of antibody. Infections were performed in triplicate; the standard deviation is shown. Similar results were obtained in two
independent experiments.
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tion by a monoclonal antibody to CD4 in P4-CCR5 indica-
tor cells expressing both CCR5 and CD4. We found that the
G382R mutant virus was less sensitive than 239wt to neu-
tralization with this mAb (Fig. 4B). These results indicate
that the G382R and V388A substitutions flanking the SIV-
mac Env C3 region modulate CD4 utilization and decrease
susceptibility to inhibition by mABs to CD4.
Finally, we analyzed the replicative capacity of the SIV-
mac239 C3 mutants in several cell types. Only the 239wt
virus and the G382R variant replicated with 239wt-like
efficiency in the T-B hybrid cell line CEMx174 expressing
CD4 and GPR15 (Fig. 5A). Despite high activity in infec-
tivity and fusion assays, the V388A variant replicated less
efficiently and with delayed kinetics. All remaining C3
mutants were grossly defective in viral replication. This
result is consistent with our finding that these SIVmac239
C3 variants enter inefficiently into 293T cells, coexpressing
CD4 and GPR15 (data not shown). Likewise, only the
G382R and V388A variants replicated to detectable levels
in rhPBMC (Fig. 5B). However, the G383R, 382RR, and
382RxxN variants, which were consistently inactive in rh-
PBMC, replicated in huPBMC albeit with delayed kinetics
and reduced efficiency compared to 239wt (example shown
in Fig. 5C). This is in agreement with with our observation
that these changes in the C3 region reduce SIVmac entry via
huCD4 less severely than infection via rhCD4 (Figs. 1B and
C). All single substitutions at position 385 (D385E, N, or G)
completely disrupted viral spread in PBMC irrespective of
their species origin. Thus, consistent with the infectivity-
data, replication of the RxxN variant in huPBMC confirms
that mutation of G382R can partially compensate for the
disruptive D385N change. Most remarkably, however, the
results clearly demonstrate that several changes in the C3
region selected in vivo render the virus completely inactive
for replication in primary rhPBMC.
Substitution of D368N in the HIV-1 Env C3 region affects
the threshold level of CD4 cell-surface expression
required for viral replication
While the crystal structure of SIV gp120 has not been
solved, the highly conserved nature of both CD4 and the C3
region in gp120 prompted us to examine HIV-1 gp120, for
which a structure is available. Residue D368 in the HIV-1
gp120, which is analogous to residue D385 in SIVmac239,
makes direct contact with amino acids F43 and R59 in the
CD4 molecule (Kwong et al., 1998) (Fig. 6A). Analogous to
the changes in the SIVmac C3 domain (Fig. 1A), we intro-
duced mutations of S365R, G366R, and D368N or G in the
Env glycoprotein of the X4-tropic HIV-1 NL4-3 clone (Fig.
6B). This molecular HIV-1 clone was utilized because it has
been already been thoroughly characterized by different
research groups. First, we infected several cell lines ex-
pressing different levels of CD4 with NL4-3 mutants con-
taining the luciferase gene in place of nef. CD4 surface
expression levels were estimated by the mean fluorescence
intensities (m.f.) after parallel staining with the CD4-spe-
cific mAb OKT4. All changes in the C3 region disrupted
HIV-1 entry into P4-CCR5 cells expressing low levels of
CD4 (m.f. 14.2) in conjunction with CXCR4 (Fig. 6C). In
contrast, the D368N substitution reduced entry into U373-
MAGI-CXCR4CEM cells (m.f. 24.6) only to about 50%
compared to NL4-3wt (Fig. 6D). Unlike the D385N muta-
tion in the SIVmac239 Env (Figs. 1B and C), no disruptive
effect of the corresponding D368N mutation in HIV-1 Env
was observed in transiently transfected 293T cells express-
ing high levels of huCD4 (m.f. 282.9) and CXCR4 (Fig.
6E). Thus, the effect of the D368N change on HIV-1 infec-
tivity was dependent on the CD4 expression levels of the
target cells. In comparison, D368G generally disrupted
HIV-1 infectivity. Unlike the corresponding change in the
SIVmac CD4 binding site, the additional substitution of
Fig. 5. Replication of SIVmac239 C3 variants in (A) CEMx174 cells and in (B) rhesus or (C) human PBMC. Cells were infected with 5 ng p27 containing
virus derived from transfected 293T cells. Virus production was monitored by assays of reverse transcriptase (RT) activity in the culture supernatants at the
indicated days post-infection. Similar results were obtained in three independent experiments. PSL, photo-stimulated light emission.
296 C. Otto et al. / Virology 315 (2003) 292–302
S365R had no restorative effects. In contrast the SD-RN
variant was clearly less infectious than the D368N mutant
virus (Figs. 6D and E). These results suggest that the SIV-
mac and HIV-1 Env proteins might interact with CD4 in a
somewhat different manner. None of the NL4-3 C3 variants
replicated above background levels in CEMx174 cells (Fig.
7A). In contrast, the D368N and SG-RR mutants spread
efficiently in PM1 cells albeit with delayed kinetics (Fig.
7B). In huPBMC only NL4-3 and D368N showed efficient
levels of replication with the spread of the D368N variant
being more dependent on the PBMC donor (examples shown
in Fig. 7C). In agreement with a previous study examining a
similar mutation of D368E (Platt et al., 1998) our results
suggest that the D368N substitution in the HIV-1 C3 region
impairs HIV-1 infectivity at low CD4 expression levels, but
has less disruptive effects at high levels of CD4 expression.
To further test this hypothesis, we infected Jurkat-T cells
expressing low or high levels of CD4 (Cortes et al., 2002)
with NL4-3 wt and the different C3 mutants. FACS analysis
confirmed that Jurkat-T high-CD4 cells expressed about
10-fold higher levels of surface CD4 than low-CD4 cells
(m.f. 218 versus 24) but similar levels of CXCR4 (m.f. 156
versus 168). As shown in Fig. 8A, only the parental HIV-1
NL4-3 clone replicated to detectable levels when Jurkat-T
low-CD4 cells were infected with virus stocks containing 5
ng p24 antigen. After infection with a 10-fold higher dose,
some inefficient and delayed replication of the D368N vari-
ant was also observed (Fig. 8B). In contrast, the D368N
mutant replicated consistently with accelerated kinetics and
higher efficiency than NL4-3wt in Jurkat cells expressing
high levels of CD4 (Figs. 8C and D). The D385G and
SD-RN mutants replicated to some extent in Jurkat cells
expressing high levels of CD4 after inoculation with virus
stocks containing 50 ng p24 antigen (Fig. 8D). However, in
agreement with the grossly defective viral entry (Fig. 6),
spread of these variants was strongly delayed and ineffi-
cient. Thus, the D368N mutation in the HIV-1 C3 region is
associated with impaired viral infectivity and replication at
low levels of CD4 cell-surface expression but accelerates
viral replication in cell expressing high levels of CD4.
Discussion
In this study, we investigated the effect of naturally
occurring sequence alterations in the SIVmac Env C3 re-
Fig. 6. HIV-1 NL4-3 C3 variants analyzed and their infectivity for target cells expressing different CD4 levels. (A) Localization of the gp120 C3 region in
the Envelope CD4 complex (Kwong et al., 1998). Residues in Env mutated in this study and amino acids F43 and R59 in CD4 are indicated. (B) Mutations
in the HIV-1 C3 region analyzed. Dashes indicate sequence identity and the numbers above the alignment refer to the amino acid position in the NL4-3 Env
sequence. (C) P4-CCR5 cells, (D) U937-MAGI-CXCR4CEM indicator cells, and (E) transiently transfected 293T cells coexpressing human CD4 and X4
were infected in triplicate with replication-competent HIV carrying the luciferase gene in place of the nef gene. Virus stocks containing normalized amounts
of p24 antigen (300 ng) were used for infection. Luciferase activities in the cellular extracts were measured at 3 days postinfection. Results were confirmed
in two independent experiments.
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gion and corresponding changes in the HIV-1 Env on viral
infectivity and replication. Mutations were introduced into
the well-characterized SIVmac239 and HIV-1 NL4-3 mo-
lecular clones. SIVmac239 had previously been utilized in
studies describing unusual sequence variations in the C3
region upon infection of rhesus macaques (Anderson et al.,
Fig. 8. Replication of HIV-1 NL4-3 C3 variants in Jurkat cells expressing differential levels of CD4. Jurkat cells expressing low (A, C) or high (B, D) levels
of CD4 were infected with virus stocks containing 5 or 50 ng p24 antigen. Results were reproduced in two independent experiments with independent virus
stocks and all constructs were verified by sequence analysis.
Fig. 7. Replication of HIV-1 NL4-3 C3 variants. (A) CEMx174 cells, (B) PM1 cells, and (C) huPBMC from two different donors were infected with 5 ng
p24 containing virus derived from transiently transfected 293T cells. Virus production was monitored as described in the legend to Fig. 4. Comparable results
were obtained in two independent experiments and when 10-fold higher viral doses were used for infection.
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1993; Campbell and Hirsch, 1994; Kodama et al., 1993;
Rudensey et al., 1995). These amino acid changes included
the substitution of a central aspartic acid residue at position
385, which likely binds CD4 directly. We demonstrate that
the D385N substitution in the SIVmac Env C3 region fa-
cilitates CD4-independent cell–cell fusion but abrogates
viral infection and that this disruptive effect is partially
compensated by the adjacent G382R substitution. The ma-
jority of the C3 substitutions selected in vivo severely im-
paired viral infectivity and replication, when introduced into
SIVmac239. These findings together with a recent report by
Ryzhova et al. (2002) suggest that additional mutations
elsewhere in the SIVmac genome must be selected to allow
effective CD4-independent viral spread in infected ma-
caques.
The amino acid changes at positions 382, 383, 385, and
388 in SIVmac 239 Env selected in experimentally infected
macaques had the following differential effects on viral
replication: (i) Individual mutations of G382R or V388A
frequently enhanced SIVmac infectivity in both the absence
and the presence of CD4. This result is consistent with the
observation that G382R is sufficient to strongly increase
SIVmac239 replication in cells expressing low levels of
CD4, similar to rhesus macaque alveolar macrophages
(Bannert et al., 2000; Mori et al., 1992, 1993, 2000), and is
present in some CD4-independent SIVmac isolates (Edinger
et al., 1997; Flaherty et al., 1997; Zhu et al., 1995). (ii) The
382RR, G383R, D385E, and RxxN changes reduced SIV-
mac infection but rendered the virus not completely inac-
tive. (iii) The remaining SIVmac239 C3 variants D385G,
382RxxG, 383RxG, 382RRxG, D385N, 383RxN, 382RRxN,
and 382RRxS were grossly defective in both viral entry and
replication. However, in agreement with a recent study
(Ryzhova et al., 2002), most of these changes enhanced
CD4-independent cell–cell fusion. Nevertheless, none of
these SIVmac239 C3 variants entered efficiently into any of
the cell types tested or replicated in primary rhesus-derived
peripheral blood mononuclear cells (PBMC). These data
indicate that results obtained with highly sensitive cell–cell
fusion assays can have limited relevance for viral infectivity
and demonstrate that changes elsewhere in Env are required
to restore efficient viral replication.
What drives the selection of these changes in infected
rhesus macaques? Further studies are required to obtain
definitive proof, but we feel that most likely the alterations
in the SIVmac Env C3 region reflect the stepwise adaptation
of SIVmac toward effective CD4-independent entry. Single
substitutions of G382R have frequently been observed in
SIVmac isolates derived from brain, lymph node, or lung
(Flaherty et al., 1997; Hill et al., 1997; Rudensey et al.,
1995; Zhu et al., 1995) and this change is sufficient to
increase viral replication in macrophages (Mori et al., 1992,
1993). This viral property might be due to efficient utiliza-
tion of low densities of CD4 for efficient infection of target
cells (Bannert et al., 2000; Mori et al., 2000). Our results
suggest that G382R increases the general fusogenic activity
of SIVmac Env and alters the interaction with CD4, result-
ing in decreased inhibition by an anti-CD4 mAB. In con-
trast, individual substitutions of D385N or D385G consis-
tently disrupted SIVmac infectivity. Remarkably, however,
these changes were frequently observed in conjunction with
the G382R substitution in infected macaques (Kodama et
al., 1993; Zhu et al., 1995). Thus, the sequence and func-
tional data suggest that G382R might be initially selected to
enhance infection at lower levels of CD4 expression. Sub-
sequently, the D385N or D385G substitutions in conjunc-
tion with additional changes in the V1/V2 and V3 region or
elsewhere in Env are selected to enhance CD4-independent
coreceptor binding and thus promote the efficient infection
of target cells that either lack or express low levels of CD4.
In support of this assumption changes across the full length
of Env have been detected in CD4-independent SIVmac
variants and contribute to infection of macrophages which
express low levels of CD4 (Anderson et al., 1993; Mori et
al., 1992; Puffer et al., 2002). This hypothesis would explain
why alterations in the SIVmac C3 region were mainly
observed in tissues, expressing low amounts of CD4 such as
brain or lung.
Several SIVmac C3 variants analyzed in this study uti-
lized huCD4 more effiently for viral infection than rhCD4
(Fig. 2). This finding resembles our previous results show-
ing that SIVmac efficiently utilizes human but not rhesus
STRL-33 for viral entry (Pohlmann et al., 2000) and further
emphasizes the importance of using receptors derived from
the appropriate species when studying Env function. We
investigated several CD4 mutants to elucidate why the SIV-
mac RxxN Env variant infected cells expressing huCD4
with about 30-fold higher efficiency than cells expressing
rhCD4 (Fig. 2). Altogether, human- and rhesus-derived
CD4 differ in 35 amino acid residues. For example, R59 in
huCD4, which forms salt bridges with N368 in HIV-1 Env
(Kwong et al., 1998) and most likely also with N385 in
SIVmac Env, is replaced by a lysine residue in rhCD4. We
found that the R59K substitution in huCD4 reduced SIVmac
RxxN entry by 50%. However, the reciprocal change in
rhCD4 did not significantly enhance infection by the mutant
virus (C. Otto and F. Kirchhoff, unpublished observations).
Thus, it remains to be clarified why huCD4 is used more
efficiently by the RxxN Env than rhCD4.
In contrast to the findings in SIVmac-infected rhesus
macaques, alterations in the HIV-1 C3 region in infected
humans were never documented. Unlike the corresponding
G382R change in SIVmac Env, substitution of S365R in
HIV-1 Env both individually and in conjunction with
D368N reduced viral infectivity and delayed or impaired
viral replication. Consistent with our functional data, sug-
gesting that S365R is not advantageous for viral spread, an
arginine is not present at this position in any of the Env
sequences in the HIV-1 sequence database. We found that
substitutions of D368N or D368G both impaired HIV-1
infectivity. Our results are in agreement with previous stud-
ies demonstrating that D368 is important for CD4 binding
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and makes direct contact with residues F43 and R59 of the
receptor (Fig. 7A) (Kwong et al., 1998; Olshevsky et al.,
1990). However, in contrast to the corresponding D385N
change in the SIVmac C3 region, which always impaired
viral infectivity, the disruptive effect of the D368N substi-
tution was dependent on the levels of CD4 expression. Our
data resemble those of Platt et al. (1998), who found that
wild-type HIV-1 efficiently infects cells expressing a wide
range of cell-surface CD4 levels, whereas a D368E mutant
virus requires substantially higher levels of CD4 for effi-
cient infection. In contrast, heterologous changes such as
D368G or D368P completely disrupt HIV-1 infection. Ex-
tending the previous study, we found that the HIV-1 NL4-3
D368N variant can spread efficiently in human PBMC.
Notably, this mutant virus replicated with accelerated kinet-
ics and greater efficiency than wild-type HIV-1 NL4-3 in
Jurkat cells expressing high surface levels of CD4. It has
been shown that CD4 inhibits virus release and might pre-
vent Env incorporation into virion or result in the incorpo-
ration of Env/CD4 complexes that are inactive in mediating
HIV-1 infection (Bour et al., 1999; Ross et al., 1999). The
lower affinity of the D368N Env for CD4 could reduce these
inhibitory effects and might allow the virus to replicate
efficiently in cells expressing high quantities of CD4. Ac-
cordingly, such variants might also have a selective advan-
tage in primary cells or tissues expressing high CD4 levels.
In summary, we show that arginine substitutions flanking
the critical aspartic acid residue in the Env C3 region en-
hance SIVmac infectivity but impair HIV-1 infectivity. This
likely explains why these mutations are only observed in
SIV mac infection. Changes of D385G or D368G generally
disrupted SIVmac and HIV-1 infectivity, respectively. In
comparison, an asparagine at position 385 consistently im-
paired SIVmac infection, whereas the corresponding change
in HIV-1 Env had no disruptive effects at high levels of
CD4 expression. The results suggest that HIV-1 and SIV-
mac Env interact with CD4 in a somewhat different manner.
The disruptive D385N or D385G changes in SIVmac Env
might only be selected as a last step in the adaptation to
CD4-independent entry. We are currently investigating
whether changes in the V1/V2 and V3 region observed in
SIVmac Env C3 variants increase the efficiency of CD4-
independent infection.
Materials and methods
Mutant construction
The SIVmac239D385E variant and all HIV-1 NL4-3 C3
mutants were generated by splice overlap extension PCR
essentially as described (Pohlmann et al., 1999). The re-
maining SIVmac239 C3 mutants (Fig. 1A) were generated
using mutagenic primers containing the MroI restriction site
at position 7761 of the proviral genome (Regier and Des-
rosiers, 1990). Briefly, the 239wt env region was amplified
using p5outV3 (5-GAGTCTTGTGACAAACA-3) and p3-
G382R (5-AGGTAACTTCCGGATCTCCTCCTCGAGG-
AGCC-3); p3-G383R (5-AGGTAACT-TCCGGATCTC-
CTCTTCCAGGA-3); p3-382RR (5-AGGTAACT-
TCCGGAT CTCCTCT-TCTAGGAGCC-3); p3-D385G
(5-AAGGTAACTTCCGGACCTCCTCCTC-3); p3-382RxxG
(5 - AGGTAACTTCCGGACCTCCTCCTCTAGGAGCC-
GT-3); p3-383RxG (5-AGGTAACTTCCGGACCTC-
CTCTTCCAGGAGCCGT-3); p3-382RRxG (5-AG-
GTAAC-TTCCGGACCTCCTCTTCTAGGAGCCGT-3);
p3-D385N (5-GAAGGTAACTTCCGG-ATTTCCTC-
CTCCAGGAGCC-3); p3-382RxxN (5-AGGTAACTTC-
CGGATTTCCTCCTCTAGGAGCCGT-3); p3-383RxN
(5-AGGTAACTTCCGGATTTCCTCTTCCAGGA-GC-3);
p3-382RRxN (5-AGGTAACTTCCGGATTTCCTCTT-
CTAGGAGCCGT-3); or pF52 (5-TTCCGGATTTCCT-
CTTCTAGGAGC-3); and p5V388A (5-GAGGAGATC-
CGGAAGCTA-CCTTCATG-3). Changes compared to
the 239wt sequence are in bold; the MroI site is underlined.
PCR products were digested with XhoI and MroI or ClaI
(V388A), gel purified, and cloned into a modified full-
length 239wt provirus (Pohlmann et al., 1999). All PCR-
derived inserts were sequenced to ensure that only the
intended changes were present. Replication-competent lu-
ciferase reporter viruses were generated by standard cloning
techniques.
Coreceptor expression vectors
Vectors expressing human and rhesus macaque CCR5
were provided by Nathaniel Landau and Preston Marx
through the AIDS Research and Reference Program, Divi-
sion of AIDS, NIAID, NIH. Expression vectors for human
GPR15 were kindly provided by Dan Littman (Skirball
Institute for Molecular Medicine, New York, NY). Vectors
expressing rhesus macaque GPR15 were generated as de-
scribed (Pohlmann et al., 1999, 2000).
Virus stocks
Generation of virus stocks was performed by the calcium
phosphate method as described (Deng et al., 1996). Briefly,
293T cells were transfected with 10 g of the full-length
proviral SIVmac239 or HIV-1 NL4-3 clones. After over-
night incubation, the medium was changed and virus was
harvested 24 h later. Viral stocks were aliquoted and frozen
at80°C. p24 and p27 antigen concentrations, respectively,
of viral stocks were quantitated with an SIV p27 antigen
capture ELISA obtained through the National Institutes of
Health AIDS Research and Reference Reagent Program.
Cells
CEMx174, PM1, and Jurkat cells were maintained in
RPMI 1640 medium supplemented with 10% FCS. sMAGI
cells (Chackerian et al., 1995), P4-CCR5, and 293T cells
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were grown in DMEM medium supplemented with 10%
FCS and antibiotics. Generation of Jurkat cells expressing
different levels of CD4 has been described previously
(Cortes et al., 2002). Peripheral blood mononuclear cells
were isolated using lymphocyte separation medium (Or-
ganon Teknika Corp., Durham, NC) stimulated for 3 days
with 2 g phytohemagglutinin per milliliter and cultured in
RPMI 1640 medium with 20% FCS and 100 U/ml IL-2.
Supernatants were collected at 3- or 4-day intervals and
virus production was measured by reverse transcriptase as-
say as described (Potts, 1990).
Entry, fusion, and antibody inhibition assays
To determine coreceptor activity of the SIV mac or
HIV-1 C3 mutants, 293T cells were transiently cotrans-
fected with CD4 and coreceptor-expression plasmids. After
overnight incubation the medium was changed and the cells
were seeded in 48-well dishes. The following day cells were
infected with stocks of the luciferase-reporter viruses con-
taining 300 ng of p27 antigen, respectively, in a total vol-
ume of 0.5 ml. At 3 days after infection cells were lysed and
the luciferase activities in 20 l cell lysates were deter-
mined using a commercially available kit (Promega). The
fusion assay was performed as described elsewhere (Puffer
et al., 2002, Rucker et al., 1997). Briefly, effector 293T cells
were infected with a vTF1.1 recombinant vaccinia virus
expressing the T7 RNA polymerase followed by CaCl2-
mediated transfection of an Env expression plasmid. QT6
target cells were cotransfected with plasmids expressing
CCR5 and/or CD4 and a T7 luciferase plasmid expressing
the luciferase gene under the control of the T7 promoter.
One day after transfection, the effector cells were overlaid
on the target cells and incubated at 37°C for 8 h to allow the
formation of syncytia. To quantify cell–cell fusion, the cells
were lysed, mixed with luciferase substrate (Promega), and
counted in a luminometer (Wallac). For antibody inhibition
experiments, P4-CCR5 cells were preincubated with the
various dilutions of mAb SK-3 pure or CD4-V4 (Becton–
Dickinson) for 1 h prior to infection with virus stocks
containing 100 ng of p27 antigen. Infectivity was quanti-
tated 3 days postinfection using the Galacto-Light Plus
chemiluminescence reporter assay kit (Tropix, Bedford,
MA) as recommended by the manufacturer.
FACS
Cells were detached by treatment with 5 mM EDTA and
washed with FACS staining buffer (1% calf serum, 0.1%
azide, in PBS). CD4 expression was determined by staining
with the anti-CD4 mAb OKT4 conjugated with phyto-
erythrin (PE) (Becton–Dickinson). Washing was repeated,
and the cells were resuspended in FACS buffer and staining
was analyzed on a FACScanner (Becton–Dickinson) with
CellQuest software.
ELISA
Supernatants were produced by infection of 293T cells
followed by transfection with the designated Env expression
plasmid. Forty-eight hours posttransfection, the medium
was harvested and filtered to remove cell debris. The su-
pernatant was applied to 96-well ELISA plates coated with
100 l Galanthus nivalis lectin (Vector Laboratories),
blocked with 2% blotto in TBS (10 g/mL in capture
buffer), and incubated overnight. Plates were then washed
and incubated with serially diluted RhCD4IgG containing
supernatant for 2 h at room temperature. Plates were again
washed and incubated with anti-rabbit horseradish peroxi-
dase (Promega) at 1:10,000 dilution for 1 h. Plates were
then washed and developed with TM Blue substrate (KPL)
and absorbance at OD630 was determined using a Dynex
MLX plate reader with Revelation software.
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